A Single and Repeat Dosing Study of the Safety, Drug Exposure, and Clinical Activity of R-3750 in Patients with Mild to Moderate Ulcerative Colitis
Latest Information Update: 09 Apr 2025
At a glance
- Drugs R 3750 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man; Proof of concept
Most Recent Events
- 07 Apr 2025 According to the Rise Therapeutics media release, first clinical results from the completed dose escalation segment will be presented at the Digestive Disease Week (DDW) Conference in San Diego May 3-6.
- 06 Jan 2025 According to the Rise Therapeutics media release, the company has completed dose escalation enrollment stages and will now initiate the planned dose expansion stages, enrolling additional patients at fixed doses in this study.
- 13 Nov 2024 Planned End Date changed from 1 Feb 2025 to 1 Oct 2025.